Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918
- 1 July 2002
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (13), 2943-2950
- https://doi.org/10.1200/jco.2002.12.116
Abstract
PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate–binding cassette drug transporter, substantially limits the oral bioavailability of...Keywords
This publication has 29 references indexed in Scilit:
- Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2000
- Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumorsCancer Chemotherapy and Pharmacology, 1999
- Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 1999
- Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Topotecan in Platinum- and Paclitaxel-Resistant Ovarian CancerGynecologic Oncology, 1997
- Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.Journal of Clinical Oncology, 1997
- Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitorBritish Journal of Cancer, 1996
- Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating FactorJNCI Journal of the National Cancer Institute, 1993
- Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitorAnnals of Oncology, 1993
- A kinetic and Mechanistic Study of the Hydrolysis of Camptothecin and Some AnaloguesJournal of Pharmaceutical Sciences, 1992